Anne Roulston

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12003773/publications.pdf

Version: 2024-02-01

14 papers	1,808 citations	759233 12 h-index	1058476 14 g-index
14 all docs	14 docs citations	14 times ranked	3021 citing authors

#	Article	IF	Citations
1	Viruses and Apoptosis. Annual Review of Microbiology, 1999, 53, 577-628.	7.3	665
2	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19512-19517.	7.1	611
3	The Small Molecule GMX1778 Is a Potent Inhibitor of NAD⁺ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors. Molecular and Cellular Biology, 2009, 29, 5872-5888.	2.3	204
4	Programming cancer cells for high expression levels of Mcl1. EMBO Reports, 2013, 14, 328-336.	4.5	63
5	Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anti-Cancer Drugs, 2009, 20, 346-354.	1.4	55
6	The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Science Translational Medicine, 2016, 8, 365ra159.	12.4	42
7	Synergy between the NAMPT Inhibitor GMX1777(8) and Pemetrexed in Nonâ€“Small Cell Lung Cancer Cells Is Mediated by PARP Activation and Enhanced NAD Consumption. Cancer Research, 2014, 74, 5948-5954.	0.9	37
8	New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology. Molecular and Cellular Oncology, 2016, 3, e1052180.	0.7	35
9	BIM, PUMA, and the Achillesâ€™ Heel of Oncogene Addiction. Science Signaling, 2013, 6, pe12.	3.6	21
10	Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim. BMC Cancer, 2015, 15, 568.	2.6	21
11	Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer. Neoplasia, 2011, 13, 339-347.	5.3	19
12	Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy. Oncotarget, 2017, 8, 77846-77859.	1.8	15
13	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anti-Cancer Drugs, 2018, 29, 774-785.	1.4	12
14	Assembly of Complex Macrocycles by Incrementally Amalgamating Unprotected Peptides with a Designed Four-Armed Insert. Journal of Organic Chemistry, 2018, 83, 3090-3108.	3.2	8